ISIS PHARMACEUTICALS EXTENDS DRUG DISCOVERY COLLABORATION WITH LILLY

Isis Pharmaceuticals today announced the extension of its antisense drug discovery collaboration with Eli Lilly and Company. As the initial four-year term of the broad, strategic alliance comes to its pre-planned end, the companies are extending their relationship and will continue to collaborate on mutually agreed targets for approximately 24 months.

Finanzen.net (http://finanzen.net/news/news_detail.asp?NewsNr=325682)